摘要
目的:观察康柏西普不同疗法对湿性年龄相关性黄斑变性(AMD)的效果。方法:回顾性分析2019年6月-2020年6月九江市第一人民医院收诊的湿性AMD患者87例87眼。根据治疗方法分为观察组(43例43眼,行康柏西普1+PRN方案),对照组(44例44眼,行康柏西普3+PRN方案),比较两组疗效及安全性。结果:两组治疗前最佳矫正视力(BCVA)、黄斑中心视网膜厚度(CRT)及中心区视网膜容积(CSV)比较,差异均无统计学意义(P>0.05),两组治疗后各时间点均优于治疗前,差异均有统计学意义(P<0.05),两组间治疗后各时间点比较,差异均无统计学意义(P>0.05)。两组的不良事件发生例次和与注射总次数比较,差异均无统计学意义(P>0.05)。两组首次、二次、四次给药间隔时间比较,差异均无统计学意义(P>0.05),观察组三次给药间隔时间明显较对照组长,差异有统计学意义(P<0.05)。结论:对湿性AMD患者采用康柏西普进行治疗时,执行1+PRN和3+PRN治疗均能保障效果和安全性,且不同的治疗方案对于药物使用次数并无明显影响,因此在对患者执行按需治疗即可。
Objective:To observe the effect of different treatments of Conbercept in wet age-related macular degeneration (AMD).Method:A total of 87 cases (87 eyes) of wet AMD admitted to Jiujiang NO.1 People’s Hospital from June 2019 to June 2020 were analyzed retrospectively.According to the treatment method,the patients were divided into observation group (43 cases,43 eyes,treated with 1+PRN regimen of Conbercept) and control group (44 cases,44 eyes,treated with 3+PRN regimen of Conbercept).The efficacy and safety of the two groups were compared.Result:There were no significant differences in the best corrected visual acuity (BCVA),macular central retinal thickness (CRT) and central subfield volume (CSV) between the two groups before treatment (P>0.05).Those of the two groups at all time points after treatment were better than those before treatment,the differences were statistically significant (P<0.05).There were no significant differences between the two groups at all time points after treatment (P>0.05).There were no significant differences in the number of adverse events and total number of injections between the two groups (P>0.05).There were no significant differences in the interval between the first,second and fourth administration of the two groups (P>0.05),the interval between the third administration of the observation group was significantly longer than that of the control group (P<0.05).Conclusion:When patients with wet AMD are treated with Conbercept,the implementation of 1+PRN and 3+PRN therapy can ensure the efficacy and safety,and different treatment plans have no significant effect on the number of drug use.Therefore,it is enough to perform on-demand treatment on patients.
作者
汪彬
屈晓勇
欧阳君
WANG Bin;QU Xiaoyong;OUYANG Jun(Jiujiang NO.1 People’s Hospital,Jiangxi Province,Jiujiang 332000,China;不详)
出处
《中国医学创新》
CAS
2022年第26期60-64,共5页
Medical Innovation of China
基金
九江市科技计划项目(201819030)。
